Chinese patients are expected to be able to buy 14 kinds of cancer drugs at a lower price from September, according to China's state medical insurance administration.
The National Healthcare Security Administration has lowered the procurement prices of 14 cancer drugs, asking pharmaceutical companies to submit price adjustment applications to provincial-level drug procurement offices, according to a recent circular issued by the administration.
The administration has also selected a range of drugs for further negotiation to be included on the country's medical insurance reimbursement list.
The drugs are all crucial in dealing with hematological neoplasms and solid tumors, and have great clinical value and huge benefits for patients, the administration said.
